NCT02600611 - Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

November 1, 2015

Primary Completion Date

January 30, 2017

Study Completion Date

January 30, 2017

Conditions

Skin Structures and Soft Tissue Infections

Interventions

DRUG

iclaprim

Experimental treatment

DRUG

vancomycin

Active comparator

Trial Locations (56)

1

Peru, Cerro de Pasco

29

Peru, Lima

Peru, San Juán de Miraflores

31

Peru, Lima

745

Puerto Rico, Río Grande

780

Puerto Rico, Ponce

1431

Bulgaria, Sofia

1527

Bulgaria, Sofia

3110

Ukraine, Kiev

4600

Latvia, Rēzekne

6100

Ukraine, Kharkiv

6847

Germany, Dessau

7608

Ukraine, Ivano-Frankivsk

18009

Ukraine, Cherkasy

20017

District of Columbia, Washington D.C.

33144

Florida, Miami

37067

Tennessee, Franklin

37094

Tennessee, Franklin

46260

Indiana, Indianapolis

48149

Germany, Münster

50937

Germany, Cologne

55131

Germany, Mainz

61037

Ukraine, Kharkiv

65025

Ukraine, Odesa

65082

Ukraine, Odesa

69000

Ukraine, Zaporizhzhya

69032

Ukraine, Zaporizhzhya

69065

Ukraine, Zaporizhzhya

76014

Ukraine, Ivano-Frankivsk

77530

Texas, Channelview

78503

Texas, McAllen

80020

Colombia, Barranquilla

90503

California, Torrance

90620

California, Buena Park

90806

California, Long Beach

91942

California, La Mesa

92056

California, Oceanside

98195

Washington, Seattle

4781151

Chile, Temuco

95350-449

California, Modesto

32770-0834

Florida, DeLand

68510-2462

Nebraska, Lincoln

LV-5417

Latvia, Daugavpils

LV3414

Latvia, Liepāja

LV-1002

Latvia, Riga

LV-1038

Latvia, Riga

Unknown

Peru, Cusco

Peru, Ica

Peru, La Libertad

Peru, Piura

Peru, San Borja

01

Peru, Lima

85-094

Poland, Bydgoszcz

10-229

Poland, Olsztyn

00-909

Poland, Warsaw

51-124

Poland, Wroclaw